Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325479 | 1.00 | TSHR (0.42) | TSHRCYP3A4DGKACES2ALDH1A1 | |
| SCHEMBL27775989 | 0.98 | TSHR (0.43) | TSHRCYP3A4DGKACES2ALDH1A1 | |
| SCHEMBL25148521 | 0.96 | TSHR (0.42) | TSHRCYP3A4DGKACES2ALDH1A1 | |
| SCHEMBL18520324 | 0.96 | TSHR (0.42) | TSHRCYP3A4DGKACES2ALDH1A1 | |
| SCHEMBL23469978 | 0.93 | CES2 (0.44) | TSHRDGKACES2MEN1THRB | |
| SCHEMBL27419973 | 0.91 | CES2 (0.47) | DGKACES2MEN1THRBHTT | |
| SCHEMBL21539314 | 0.91 | MEN1 (0.46) | TSHRCYP3A4DGKACES2MEN1 | |
| SCHEMBL4005309 | 0.91 | CES2 (0.47) | DGKACES2MEN1THRBHTT | |
| SCHEMBL21539334 | 0.89 | MEN1 (0.48) | DGKACES2MEN1THRBHTT | |
| SCHEMBL21539433 | 0.89 | MEN1 (0.48) | DGKACES2MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | TSHR 218/4885CYP3A4 1321/4885DGKA 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.